iRhythm Technologies (NASDAQ:IRTC) reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets. iRhythm expects VitalConnect to contribute positively to revenue growth beginning in 2027. During the quarter, iRhythm signed two commercial agreements through its partnership with Lucem to combine predictive identification workflows with iRhythm monitoring. For 2026, iRhythm raised revenue guidance to $880 million to $890 million, representing growth of 18% to 19%. About iRhythm Technologies (NASDAQ:IRTC)iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services.